Survodutide met its primary cardiovascular safety endpoint in the Phase 3 SYNCHRONIZE-CVOT trial, showing significant cardiometabolic benefits including weight loss of up to 13.7% at 72 weeks, prompting Boehringer Ingelheim to move forward with global regulatory filings.
The Phase 3 SYNCHRONIZE-CVOT trial met its primary endpoint (HR 0.89, p<0.0001 for non-inferiority), completing the registrational SYNCHRONIZE program, and Boehringer Ingelheim is moving forward with global regulatory submissions in obesity. For Zealand, survodutide's partner and a core pipeline asset, de-risking of the pivotal program plus imminent filings is a material value driver. Counterpoint: the drug is not yet approved, and GI discontinuation rates reached 19.3-20.8% versus 1.9% on placebo.
Zealand Pharma and partner Boehringer Ingelheim announced positive results from the Phase 3 SYNCHRONIZE-CVOT trial, confirming the cardiovascular safety of the glucagon/GLP-1 dual agonist survodutide. The trial met its primary endpoint with a hazard ratio of 0.89, clearing the path for global regulatory submissions in obesity.
Zealand Pharma announced the results itself and survodutide is a drug from its partnership with Boehringer Ingelheim, so positive Phase 3 data and upcoming regulatory filings in obesity directly affect the value of Zealand's pipeline.
No. The press release states survodutide has not been approved for use; the trial result clears the way for global regulatory submissions in obesity.